Ibrutinib, a first-generation BTK inhibitor (BTKi), has shown antitumor activity in patients with relapsed/refractory (R/R) PCNSL as monotherapy or combination therapy [10–12]. This evidence concerns the gene BTK and primary central nervous system lymphoma.